Table 1 Patient and tumour characteristics according to age categories and treatment arm.
Characteristic | Age analysis set | |||
|---|---|---|---|---|
<65 years, n = 201 (50.2%) | ≥65 years, n = 199 (49.8%) | |||
FOLFIRI + cetuximab | FOLFIRI + bevacizumab | FOLFIRI + cetuximab | FOLFIRI + bevacizumab | |
Treatment arm, n (%) | 100 (49.8) | 101 (50.2) | 99 (49.7) | 100 (50.3) |
Gender, n (%) | ||||
Male | 79 (79) | 62 (61.4) | 67 (67.7) | 71 (71) |
Female | 21 (21) | 39 (38.6) | 32 (32.3) | 29 (29) |
ECOGa performance status, n (%) | ||||
0 | 60 (60) | 59 (58.4) | 46 (46.5) | 50 (50) |
1 | 39 (39) | 40 (39.6) | 51 (51.5) | 49 (49) |
2 | 1 (1) | 2 (2) | 2 (2.0) | 1 (1) |
BRAF status, n (%) | ||||
RAS wt/BRAF wt | 89 (89) | 86 (85.1) | 86 (86.9) | 91 (91) |
RAS wt/BRAF mut | 11 (11) | 15 (14.9) | 11 (11.1) | 9(9) |
Unknown | 2 (2) | |||
Molecular pathology | n = 158 | n = 156 | ||
dMMR n (%) | 2 (1.3) | 2 (1.3) | ||
Molecular pathology | n = 201 | n = 199 | ||
BRAFV600E | 26 (12.9) | 20 (10.3) | ||
Molecular pathology | n = 197 | n = 195 | ||
PIK3CA | 8 (4.1) | 17 (9.2) | ||
Side of primary tumour, n (%) | ||||
Left (splenic flexure-rectum) | 85 (85) | 79 (78.2) | 74 (74.7) | 70 (70) |
Right (transverse colon-caecum) | 14 (14) | 22 (21.8) | 24 (24.2) | 30 (30) |
Unknown | 1 (1) | 1 (1) | ||
Site of primary tumour, n (%) | ||||
Colon | 57 (57) | 59 (58.4) | 62 (62.6) | 67 (67) |
Rectosimgoid | 5 (5) | 3 (3) | 3 (3) | 4 (4) |
Rectum | 37 (37) | 39 (38.6) | 34 (34.3) | 29 (29) |
Unknown | 1 (1) | |||
Grading, n (%) | ||||
G1 | 4 (4) | 1 (1) | 1 (1) | |
G2 | 59 (59) | 71 (71) | 68 (68.7) | 63 (63) |
G2–3 | 1 (1) | 2 (2) | 3 (3) | |
G3 | 30 (30) | 26 (26) | 25 (25.3) | 30(30) |
GX | 6 (6) | 3 (3) | 4 (4) | 3(3) |
Number of metastatic sites, No. (%) | ||||
1 site | 43 (43) | 42 (42) | 42 (42.4) | 41 (41) |
≥2 sites | 56 (56) | 57 (57) | 56 (56.6) | 59 (59) |
Unknown | 1 (1) | 1 (1) | 1 (1) | |
Metastatic sites (selected), No. (%) | ||||
Liver limited | 36 (36) | 30 (30) | 35 (35.4) | 32 (32) |
Lung | 34 (34) | 33 (33) | 38 (38.4) | 42 (42) |
